Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab.

van der Heijde D, Breban M, Halter D, DiVittorio G, Bratt J, Cantini F, Kary S, Pangan AL, Kupper H, Rathmann SS, Sieper J, Mease PJ.

Rheumatology (Oxford). 2015 Jul;54(7):1210-9. doi: 10.1093/rheumatology/keu438. Epub 2014 Dec 25.

2.

Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates.

Dore RK, Cohen SB, Lane NE, Palmer W, Shergy W, Zhou L, Wang H, Tsuji W, Newmark R; Denosumab RA Study Group.

Ann Rheum Dis. 2010 May;69(5):872-5. doi: 10.1136/ard.2009.112920. Epub 2009 Sep 3.

PMID:
19734132
3.

Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.

Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, Pazdur J, Bae SC, Palmer W, Zrubek J, Wiekowski M, Visvanathan S, Wu Z, Rahman MU; GO-FORWARD Study.

Ann Rheum Dis. 2009 Jun;68(6):789-96. doi: 10.1136/ard.2008.099010. Epub 2008 Dec 9. Erratum in: Ann Rheum Dis. 2011 Jan;70(1):238.

4.

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial.

van der Heijde D, Schiff MH, Sieper J, Kivitz AJ, Wong RL, Kupper H, Dijkmans BA, Mease PJ, Davis JC Jr; ATLAS Study Group.

Ann Rheum Dis. 2009 Jun;68(6):922-9. doi: 10.1136/ard.2007.087270. Epub 2008 Aug 13.

5.

Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS).

Revicki DA, Luo MP, Wordsworth P, Wong RL, Chen N, Davis JC Jr; ATLAS Study Group.

J Rheumatol. 2008 Jul;35(7):1346-53. Epub 2008 May 15. Erratum in: J Rheumatol. 2011 Apr;38(4):788.

PMID:
18484692
6.

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial.

Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, van der Heijde D, Zhou L, Tsuji W, Newmark R; Denosumab Rheumatoid Arthritis Study Group.

Arthritis Rheum. 2008 May;58(5):1299-309. doi: 10.1002/art.23417.

7.

Examining the relationship between bone mineral density and fracture risk reduction during pharmacologic treatment of osteoporosis.

Divittorio G, Jackson KL, Chindalore VL, Welker W, Walker JB.

Pharmacotherapy. 2006 Jan;26(1):104-14. Review.

PMID:
16506352
8.

The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions.

Schiff MH, DiVittorio G, Tesser J, Fleischmann R, Schechtman J, Hartman S, Liu T, Solinger AM.

Arthritis Rheum. 2004 Jun;50(6):1752-60.

Supplemental Content

Loading ...
Support Center